Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

HIV affects not only your physical health but also your mental health. We reviewed online support groups for the disease, so ...

Advancements in medicine and public health strategies continue to reshape the HIV landscape. The future of prevention lies in expanding access to innovative treatment options and developing new ...

including newly recommended HIV regimens. Experts And Viewpoints, April 29, 2015 The Year in HIV: Prevention, Treatment, Complications, Cure Dr Paul Sax reviews the top stories in HIV medicine in ...

Analysis Reveals an Additional Mechanism Behind Statin Therapy's Heart-Related Benefits in People With HIV Dec. 11, 2024 — Investigators who previously found that a daily statin pill helps ...

Researchers identified three new all-oral drug regimens that include at least one of two new drugs for treatment of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Human immunodeficiency virus (HIV) is a virus that attacks the body's immune system. HIV is a manageable chronic condition. With treatment, people living with HIV can have long and healthy lives.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024. "Gilead delivered another exceptionally ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...